AlphaCore Capital’s CRISPR Therapeutics CRSP Stock Holding History

AlphaCore Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$643K	Buy	+11,622	New	+$627K	0.01%	682

Other funds holding CRSP

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

AlphaCore Capital's CRSP Position: Q3 2026 in Review

AlphaCore Capital opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 11,622 shares worth $643K. The stake represents 0.01% of the portfolio and ranks #682 among its holdings.

236 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

AlphaCore Capital held 11,622 shares of CRISPR Therapeutics worth $643K as of Q3 2026.
CRISPR Therapeutics was a new AlphaCore Capital position in Q3 2026.
CRISPR Therapeutics made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #682 holding.
236 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.